Cargando…

Antineoplastic prescription among patients with colorectal cancer in eight major cities of China, 2015–2019: an observational retrospective database analysis

OBJECTIVES: It is unclear what is driving rising colorectal cancer (CRC) treatment costs in China, whether an adjustment in drug prices changes use and total cost. This study aims to estimate trends in drug use, prescribing patterns and spending for antineoplastic drug therapies for CRC in major cit...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Difei, Yu, Lingyan, He, Wei, Hu, Yangmin, Xu, Huimin, Yuan, Ying, Dai, Haibin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552170/
https://www.ncbi.nlm.nih.gov/pubmed/34706945
http://dx.doi.org/10.1136/bmjopen-2020-046166
_version_ 1784591322889322496
author Yao, Difei
Yu, Lingyan
He, Wei
Hu, Yangmin
Xu, Huimin
Yuan, Ying
Dai, Haibin
author_facet Yao, Difei
Yu, Lingyan
He, Wei
Hu, Yangmin
Xu, Huimin
Yuan, Ying
Dai, Haibin
author_sort Yao, Difei
collection PubMed
description OBJECTIVES: It is unclear what is driving rising colorectal cancer (CRC) treatment costs in China, whether an adjustment in drug prices changes use and total cost. This study aims to estimate trends in drug use, prescribing patterns and spending for antineoplastic drug therapies for CRC in major cities of China. METHODS: Information from 128 811 antineoplastic drug prescriptions in CRC was retrospectively collected from the Hospital Prescription Analysis Cooperative Project. The prescriptions extracted included demographic information of patients, the generic name and the price of antineoplastic drugs. The Mann-Kendall and Cochran-Armitage trend test was used to estimate the trends of antineoplastic agent usage. RESULTS: The number of antineoplastic prescriptions ranged from 18 966 in 2015 to 34 219 in 2019. Among the prescriptions collected in this study, the annual cost of antineoplastic drugs increased by 117.2%, and average prescription cost increased by 20%. Throughout the study period, the most prescribed antineoplastic drugs were capecitabine, oxaliplatin, fluorouracil and irinotecan, representing 49%, 27%, 21% and 9% of (per cent of visits (PV)). The PV of bevacizumab and cetuximab increased by 494% and 338% (from 1.8% and 1.3% in 2015 to 10.7% and 5.7% in 2019). In prescribing patterns of antineoplastic agents, monotherapy gradually decreased, while combination therapy, especially three-drug combination, increased significantly from 1.35% to 7.31%. CONCLUSION: This study estimated recent trends of antineoplastic drug use and expenditure for Chinese patients with CRC. These results would inform CRC treatment decisions, including health insurance negotiation, precision therapy access, allocation of research funding and evaluation of the financial burden of CRC drug treatment.
format Online
Article
Text
id pubmed-8552170
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-85521702021-11-10 Antineoplastic prescription among patients with colorectal cancer in eight major cities of China, 2015–2019: an observational retrospective database analysis Yao, Difei Yu, Lingyan He, Wei Hu, Yangmin Xu, Huimin Yuan, Ying Dai, Haibin BMJ Open Pharmacology and Therapeutics OBJECTIVES: It is unclear what is driving rising colorectal cancer (CRC) treatment costs in China, whether an adjustment in drug prices changes use and total cost. This study aims to estimate trends in drug use, prescribing patterns and spending for antineoplastic drug therapies for CRC in major cities of China. METHODS: Information from 128 811 antineoplastic drug prescriptions in CRC was retrospectively collected from the Hospital Prescription Analysis Cooperative Project. The prescriptions extracted included demographic information of patients, the generic name and the price of antineoplastic drugs. The Mann-Kendall and Cochran-Armitage trend test was used to estimate the trends of antineoplastic agent usage. RESULTS: The number of antineoplastic prescriptions ranged from 18 966 in 2015 to 34 219 in 2019. Among the prescriptions collected in this study, the annual cost of antineoplastic drugs increased by 117.2%, and average prescription cost increased by 20%. Throughout the study period, the most prescribed antineoplastic drugs were capecitabine, oxaliplatin, fluorouracil and irinotecan, representing 49%, 27%, 21% and 9% of (per cent of visits (PV)). The PV of bevacizumab and cetuximab increased by 494% and 338% (from 1.8% and 1.3% in 2015 to 10.7% and 5.7% in 2019). In prescribing patterns of antineoplastic agents, monotherapy gradually decreased, while combination therapy, especially three-drug combination, increased significantly from 1.35% to 7.31%. CONCLUSION: This study estimated recent trends of antineoplastic drug use and expenditure for Chinese patients with CRC. These results would inform CRC treatment decisions, including health insurance negotiation, precision therapy access, allocation of research funding and evaluation of the financial burden of CRC drug treatment. BMJ Publishing Group 2021-10-27 /pmc/articles/PMC8552170/ /pubmed/34706945 http://dx.doi.org/10.1136/bmjopen-2020-046166 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Pharmacology and Therapeutics
Yao, Difei
Yu, Lingyan
He, Wei
Hu, Yangmin
Xu, Huimin
Yuan, Ying
Dai, Haibin
Antineoplastic prescription among patients with colorectal cancer in eight major cities of China, 2015–2019: an observational retrospective database analysis
title Antineoplastic prescription among patients with colorectal cancer in eight major cities of China, 2015–2019: an observational retrospective database analysis
title_full Antineoplastic prescription among patients with colorectal cancer in eight major cities of China, 2015–2019: an observational retrospective database analysis
title_fullStr Antineoplastic prescription among patients with colorectal cancer in eight major cities of China, 2015–2019: an observational retrospective database analysis
title_full_unstemmed Antineoplastic prescription among patients with colorectal cancer in eight major cities of China, 2015–2019: an observational retrospective database analysis
title_short Antineoplastic prescription among patients with colorectal cancer in eight major cities of China, 2015–2019: an observational retrospective database analysis
title_sort antineoplastic prescription among patients with colorectal cancer in eight major cities of china, 2015–2019: an observational retrospective database analysis
topic Pharmacology and Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552170/
https://www.ncbi.nlm.nih.gov/pubmed/34706945
http://dx.doi.org/10.1136/bmjopen-2020-046166
work_keys_str_mv AT yaodifei antineoplasticprescriptionamongpatientswithcolorectalcancerineightmajorcitiesofchina20152019anobservationalretrospectivedatabaseanalysis
AT yulingyan antineoplasticprescriptionamongpatientswithcolorectalcancerineightmajorcitiesofchina20152019anobservationalretrospectivedatabaseanalysis
AT hewei antineoplasticprescriptionamongpatientswithcolorectalcancerineightmajorcitiesofchina20152019anobservationalretrospectivedatabaseanalysis
AT huyangmin antineoplasticprescriptionamongpatientswithcolorectalcancerineightmajorcitiesofchina20152019anobservationalretrospectivedatabaseanalysis
AT xuhuimin antineoplasticprescriptionamongpatientswithcolorectalcancerineightmajorcitiesofchina20152019anobservationalretrospectivedatabaseanalysis
AT yuanying antineoplasticprescriptionamongpatientswithcolorectalcancerineightmajorcitiesofchina20152019anobservationalretrospectivedatabaseanalysis
AT daihaibin antineoplasticprescriptionamongpatientswithcolorectalcancerineightmajorcitiesofchina20152019anobservationalretrospectivedatabaseanalysis